| Name used publicly | Layne Norton, PhD | Posts as @biolayne. Uses the PhD consistently and does not present as a physician. |
| Name we can corroborate | Layne Norton | Same name across his university thesis, his publisher, three businesses and every platform.University of Illinois thesis record, company sites |
| How they describe themselves | Dad. Natural Pro BBer. Nutritional Sci. PhD, 5x Powerlifting Nat Champ. 2x M1 World Champ. BS Crusher. @carbondietcoach co-founder | His X bio, verbatim. |
| Country | United States | Inferred from business listings, not measured |
| support@outworknutrition.com | A customer-support inbox for his supplement company, staffed by his business. It is not a way to reach him and it is not a professional address. No personal or business email for him is published anywhere. | |
| Phone | 833-688-9675 | Toll-free customer-support line for the supplement company. Same caveat: a storefront number, not his. He has no NPPES record, so there is no practice phone to fall back on. |
| Website | biolayne.com | Coaching, courses and the REPS research review. Unlike the other DIs here he does publish a general site about his work, not just sales pages. He also runs outworknutrition.com and co-founded the Carbon Diet Coach app.Instagram and X bio links, redirects followed to their destination |
| How sure we are this is one person | High | A named doctoral thesis, a competitive athletic record with published results, and three companies all trace to the same person. Unusually well corroborated for someone with no provider record. |
| Why this is a DI and not a DOL | No NPI. He is not a healthcare provider of any kind | NPPES returns zero results for this name. He holds no clinical license, cannot prescribe, has no taxonomy and appears in no provider registry. There is no IQVIA prescribing to cross-reference and never will be. This is the clean DI case: real expertise, real audience, no clinical credential and no registry anchor at all. |
The central question for a DI. A qualification can be entirely real and still not cover the subject they speak on.
| Title they use | PhD | Used as a suffix, not as 'Dr.' in a clinical sense. He does not claim to be a physician. |
| Qualifications they hold |
| Doctoral research on leucine and muscle protein synthesis, supervised by Donald Layman. The thesis is a real, citable piece of work in the field he speaks on. |
| Awarded by | University of Illinois at Urbana-Champaign | Institution |
| Independently confirmed | Empty | Nothing confirmed. Every qualification above is the person’s own claim about themselves. NASM and the NSCA both run free public verification lookups, so an NCCA-accredited certification can be confirmed in about a minute; a university degree needs the registrar. |
| Licensed to practice | Empty | He holds no clinical license anywhere, and does not claim one. A PhD is an academic qualification, not a license to practice, and he is explicit about that distinction. |
| Does the qualification cover what they talk about | Aligned, with one boundary | His doctorate is in nutritional sciences and most of his content is nutrition, training and body composition, which his qualification covers directly. GLP-1 pharmacology sits at the edge of it: he is qualified to read and explain the trial literature, and is not qualified to advise on prescribing, dosing or clinical management. His posts stay on the correct side of that line.Qualification compared against measured topic mix |
| Clinicians on the team | Empty | No clinician is named as reviewing his content. He is not making individual clinical recommendations, so this matters less here than for a DI who advises on medication use. |
A DI's influence rarely rests on credentials. Naming what it does rest on is the point of this section.
| Basis of authority | Domain qualification plus competitive record | Unusually for a DI, the qualification genuinely covers the subject. His audience was built on evidence-based nutrition content and a documented athletic career, not on contrarianism or a single protocol. |
| Books and rankings | Fat Loss Forever | Co-authored. |
| Mainstream media presence | The Dr. Layne Norton Podcast · 35 episodes | His own show, plus frequent guest appearances on large health podcasts. |
| Who amplifies them | Empty | Not yet checked. Nobody has looked at who amplifies them. |
| Work they wrote themselves | Empty | Not yet checked. Nobody has searched for work published under their own byline. |
| Peer-reviewed publications | Empty | Not searched. Run the author search and record the result, because a verified zero is a finding and an unchecked blank is not. |
| Selected posts on their own site | Empty | Not yet checked. Nobody has catalogued what they publish on their own site. |
| Podcast interviews given | Empty | Not yet checked. Nobody has searched for podcast appearances as a guest. |
The full set of researched channels. Listed here whether or not Layne Norton is active.
| Platform | Handle | Followers | Notes |
|---|---|---|---|
| @biolayne | 1,211,946 followers | exact | |
| YouTube | @biolayne1 | 439K subscribers | 1,268 videos. YouTube publishes this rounded, so it is not exact. |
| TikTok | Empty | We searched and found no TikTok account. | |
| X | @biolayne | 232,597 followers | 411 original posts in the 52-week window, reposts and replies excluded at the API. |
| Podcasts (transcribed via STT for accuracy and thoroughness) | The Dr. Layne Norton Podcast · 35 episodes | ||
| Newsletter or Substack | Empty | No newsletter or Substack found. | |
| @biolayne | 38,000 followersA personal profile, not verified by Meta. Listed under "Public figure". |
Who the followers actually are. Reach alone does not tell you whether an audience is real or relevant.
| Total reach | ~1,482,543 | Largest single-platform following, not a sum. The same person can follow on more than one platform. |
| Audience age profile | Empty | We cannot tell you the age of this audience. No vendor is wired for it. This is the single most requested field we cannot answer. |
| Audience gender split | Empty | We cannot tell you the gender split. Same reason: no audience-analytics vendor is wired. |
| Audience geography | Empty | We cannot tell you where the followers are, so we cannot confirm this is a US audience. |
| Bot / inauthentic share | Empty | We cannot tell you what share of the audience is fake. |
| Engagement rate | Empty | Not calculated. It needs likes and comments per post averaged against follower count across every platform. |
Their own content, counted. Not what others say about them.
| Layne Norton's original 52-week posts | 90 posts | Last 52 weeks: 90 on Instagram. Reposts and replies excluded. |
| Topic mix |
| Of 1,121 passages read. A passage can carry more than one topic, so these add up to more than the total.A passage is one unit of related text that AI reads and labels. A post or podcast may contain multiple passages. |
| On-topic posts | 1,018 of 1,121 measured passages (90.8%) | Their own posts plus podcast transcripts. |
| Impressions on on-topic posts | Empty | Coming soon |
| Stance | 12:3 positive to negative | 18 statements about these drugs, 3 of them neutral. |
Which brands they name and how they treat them.
| Class-level, no brand named | 18 of 18 (100%) | Passages discussing the drug class or a molecule with no product named. |
| NNI brand only | 0 of 18 (0%) | Ozempic, Rybelsus, or Wegovy named, and no competitor product. |
| Competitor brand only | 0 of 18 (0%) | Mounjaro, Zepbound, or Foundayo named, and no NNI product. |
| Both NNI and competitor | 0 of 18 (0%) | One passage naming products from both. |
A DI is not bound by professional standards, a licensing board or a promotional code. What they assert is therefore worth checking on its own terms.
| Signature claim | Evidence over anecdote | His brand is built on debunking unsupported nutrition claims, including from other influencers. |
| Evidence they cite for it | Empty | Not yet checked. Nobody has examined what they cite. |
| Documented criticism from qualified professionals | Empty | No published critique from a named qualified professional was found. He is more often the one publishing critiques of others. |
| Safety concern raised by others | Empty | No published safety concern found. He does not advise on dosing or on starting and stopping medication. |
| Retractions or corrections | Empty | Not yet checked. Nobody has looked for a public correction or retraction. |
For a DI the commercial model is usually the business, not a footnote. It shapes what they can afford to say. One quick test: follow the link in their bio. A clinician's link usually leads to a practice that treats patients. An influencer's usually leads to a place that sells you something.
| Where their links lead | His own site, then several businesses | The exception here. His links lead to a general site about his work, and separately to a supplement company and a nutrition app he co-founded. He publishes something to read, not only something to buy.Instagram and X bio links, redirects followed to their destination |
| How they make money | Coaching, an app, supplements, courses and a research review | Audience-monetized across several businesses. No employer, insurer or institution between him and his income. |
| Sells supplements or products | Yes — Outwork Nutrition | His own supplement company. Relevant because supplement founders are the group most often accused of positioning against pharmacotherapy, and he does the opposite. |
| Sells a program or membership | Yes — Biolayne coaching, courses, and Carbon Diet Coach | Co-founder of the Carbon Diet Coach nutrition app. |
| Does the business compete with the drug class | None detected — and worth stating | He sells nutrition coaching and supplements to the same audience GLP-1s are prescribed to, which is the structural setup for a commercial conflict. He does not take it. He is supportive of the drug class in public while selling the lifestyle side, and argues the two belong together. That is the opposite of the pattern flagged on other profiles. |
| Declared sponsorships | Empty | No declared sponsorship found in the 411 posts measured. Undisclosed arrangements would not be visible to us. |
| Any pharmaceutical relationship | Empty | We do not collect this. CMS Open Payments covers clinicians with an NPI, and a DI by definition has none — so the usual transparency route does not apply. |
Stance is the speaker's own evaluative position toward a GLP-1 drug, judged from a single passage. It has three values: positive, negative, or neutral.
It is measured twice. Once per passage and brand, so a passage praising one product while attacking another produces two rows with opposite stances. And once per passage overall, which is what the pie counts, so nobody is weighted up simply for naming more products in one breath.
A deterministic filter comes first. A database pattern over the six tracked brands, seven molecules and the class terms decides which passages a model ever sees. Only about 5% qualify; the rest are never sent anywhere.
Every signed opinion must carry a verbatim quote. The model is told to copy, word for word, the clause in which the speaker evaluates the product. If no such clause exists, the answer is neutral.
The quote is then checked in code, not trusted. It is stripped to letters and digits, must be at least 12 characters, and must actually appear in the source text. Fail, and the label is demoted to neutral automatically.
An adversarial second pass re-reads each signed clause alone, with no surrounding passage and no author, and asks whether it really carries that opinion. 249 of 1,140 signed labels, 21.8%, were demoted to neutral by that pass.
Not sentiment about the post. Enthusiasm aimed at anything other than the drugs is neutral toward the drugs.
Not a guess at which product. A brand is attached only when the passage prints the brand name.
Not confused by the hormone. GLP-1 is also something the gut releases after eating. Praising fiber for triggering satiety hormones is not praising Ozempic.
Why neutral dominates. Most clinical mentions of a drug are explanatory rather than evaluative, and both the verbatim-quote rule and the adversarial pass push borderline cases toward neutral rather than toward a signed opinion.